4,5-DIMETHOXYCANTHIN-6-ONE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	ATONBUGCNDSBBC-UHFFFAOYSA-N
Smiles	COC1=C(OC)c2nccc3c4ccccc4n(C1=O)c23
InChI	InChI=1S/C16H12N2O3/c1-20-14-12-13-10(7-8-17-12)9-5-3-4-6-11(9)18(13)16(19)15(14)21-2/h3-8H,1-2H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H12N2O3
Molecular Weight	280.28
AlogP	2.27
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	2.0
Polar Surface Area	53.35
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	21.0

Assay Description	Organism	Bioactivity
Antiviral activity against Tobacco mosaic virus U1 (TMV) infected Nicotiana tabacum cv. K326 leaves assessed as inhibition of viral replication in presence of 25 ug/mL quassinoid nigakilactone B measured 48 hr after compound exposure by leaf-disk method	Tobacco mosaic virus	130000.0 nM
Antiviral activity against Tobacco mosaic virus U1 (TMV) infected Nicotiana tabacum cv. K326 leaves assessed as inhibition of viral replication measured 48 hr after compound exposure by leaf-disk method	Tobacco mosaic virus	189000.0 nM
Antiviral activity against Tobacco mosaic virus U1 (TMV) infected Nicotiana glutinosa leaves assessed as inhibition of viral infection at 50 ug/mL using compound pre-treated virus suspension measured 5 to 6 days after compound exposure	Tobacco mosaic virus	58.3 %
Antiviral activity against Tobacco mosaic virus U1 (TMV) infected Nicotiana glutinosa leaves assessed as inhibition of viral infection at 50 ug/mL using compound pre-treated virus suspension in presence of 25 ug/mL quassinoid nigakilactone B measured 5 to 6 days after compound exposure	Tobacco mosaic virus	61.1 %
Antiviral activity against Tobacco mosaic virus U1 (TMV) infected Nicotiana tabacum cv. K326 leaves assessed as inhibition of viral replication at 50 ug/mL in presence of 25 ug/mL quassinoid nigakilactone B measured 48 hr after compound exposure by leaf-disk method	Tobacco mosaic virus	59.0 %
Antiviral activity against Tobacco mosaic virus U1 (TMV) infected Nicotiana tabacum cv. K326 leaves assessed as inhibition of viral replication at 50 ug/mL measured 48 hr after compound exposure by leaf-disk method	Tobacco mosaic virus	42.6 %
Antiviral activity against Tobacco mosaic virus U1 (TMV) infected Nicotiana glutinosa leaves assessed as inhibition of viral replication at 50 ug/mL in presence of 25 ug/mL quassinoid nigakilactone B measured 48 hr after compound exposure by half leaf method	Tobacco mosaic virus	43.8 %
Antiviral activity against Tobacco mosaic virus U1 (TMV) infected Nicotiana glutinosa leaves assessed as inhibition of viral replication at 50 ug/mL measured 48 hr after compound exposure by half leaf method	Tobacco mosaic virus	33.3 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2386324
PubChem	638215

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).